0001357993-17-000005.txt : 20170315 0001357993-17-000005.hdr.sgml : 20170315 20170315113041 ACCESSION NUMBER: 0001357993-17-000005 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170315 DATE AS OF CHANGE: 20170315 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TRINITY BIOTECH PLC CENTRAL INDEX KEY: 0000888721 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-44122 FILM NUMBER: 17690248 BUSINESS ADDRESS: STREET 1: IDA BUSINESS PARK, BRAY, CO WICKLOW STREET 2: IRELAND CITY: DUBLIN IRELAND STATE: L2 ZIP: 18 BUSINESS PHONE: 01135312955111 MAIL ADDRESS: STREET 1: 3 ROCK ROAD STREET 2: SANDYFORD INDUSTRIAL ESTATES CITY: DUBLIN IRELAND STATE: L2 ZIP: 18 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Lapides Asset Management, LLC CENTRAL INDEX KEY: 0001357993 IRS NUMBER: 134300774 STATE OF INCORPORATION: CT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 500 WEST PUTNAM AVENUE CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: (203) 422-7202 MAIL ADDRESS: STREET 1: 500 WEST PUTNAM AVENUE CITY: GREENWICH STATE: CT ZIP: 06830 SC 13G 1 LAMTRIB13G-.txt LAMTRIB13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Trinity Biotech plc (Name of Issuer) American Depository Shares (Title of Class of Securities) 896438306 (CUSIP Number) 03/06/2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X]Rule 13d-1(b) [ ]Rule 13d-1(c) [ ]Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 896438306 1. Names of Reporting Persons. Lapides Asset Management, LLC 13-4300774 2. Check the Appropriate Box if a Member of a Group Not Applicable 3. SEC Use Only 4. Citizenship or Place of Organization Connecticut Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 947,200 6. Shared Voting Power none 7. Sole Dispositive Power 1,214,200 8. Shared Dispositive Power None 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,214,200 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11. Percent of Class Represented by Amount in Row (9) 5.1% 12. Type of Reporting Person (See Instructions) IA CUSIP No. 896438306 ITEM 1. (a) Name of Issuer: Trinity Biotech plc (b) Address of Issuer's Principal Executive Offices: IDA Business Park Bray, Co Wicklow, Ireland L2 18 ITEM 2. (a) Name of Person Filing: Lapides Asset Management, LLC ("Lapides") (b) Address of Principal Business Office, or if None, Residence: 500 W. Putnam Avenue 4th Floor Greenwich, CT 06830 (c) Citizenship: Lapides is a Connecticut limited liability company (d) Title of Class of Securities: American Depository Shares (e) CUSIP Number: 896438306 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d -2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (e) [X] An investment adviser in accordance with ss.240.13d- 1(b)(1)(ii)(E) ITEM 4. OWNERSHIP. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: See Item 9 of Cover Pages (b) Percent of class: see Item 11 of Cover Pages (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote See Item 5 of Cover Pages. (ii) Shared power to vote or to direct the vote See Item 6 of Cover Pages. (iii) Sole power to dispose or to direct the disposition of See Item 7 of Cover Pages. (iv) Shared power to dispose or to direct the disposition of See Item 8 of Cover Pages. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. Not Applicable ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Funds managed on a discretionary basis by Lapides Asset Management are known to have the right to receive or the power to direct the receipt of dividends from, ot proceeds from the sales of such securities. None of the partners or funds beneficially own more than 5% of the stock. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. Not applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. Not applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Not Applicable ITEM 10. CERTIFICATION. (a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. (b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. March 15, 2017 (Date) James F. Betz (Signature) James F. Betz, Chief Operating Officer (Name/Title) The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties for whom copies are to be sent. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)